
Tranexamic acid for PPH: what, who and when


Postpartum Hemorrhage Community of Practice Annual Meeting 2022

Amy Brenner


Epidemiologist, London School of Hygiene & Tropical Medicine

What is tranexamic acid?





How does it stop bleeding?




What is the evidence for use in PPH?

TRANEXAMIC ACID

A drug that stops bleeding

Results from the WOMAN trial



The drug could save

women who would otherwise bleed to death after childbirth

An estimated 100,000 women die from severe bleeding after giving birth every year



The drug reduced the number of women bleeding to death after childbirth by more than 30%



The drug reduced the need for urgent surgery to control bleeding by more than 35%

£2 (\$2.5)

20,000 WOMEN 21 COUNTRIES

193 HOSPITALS

The cost of tranexamic acid in most countries

Source: The WOMAN trial (2017) Credit: Rebeccah Robinson/LSHTM

Find out more at womantrial.lshtm.ac.uk

WOMAN trial results

Outcome	TXA n (%)	Placebo n (%)	Risk ratio (95% CI)
Death due to bleeding (all women)	155 (1.5%)	191 (1.9%)	0.81 (0.65-1.00)
Death due to bleeding (women randomised <3h of birth)	89 (1.2%)	127 (1.7%)	0.69 (0.52-0.91)
Re-operation for bleeding	82 (0.8%)	127 (1.3%)	0.64 (0.49-0.85)
Thromboembolic event	30 (0.3%)	34 (0.3%)	0.88 (0.54-1.43)



Updated WHO recommendation on intravenous tranexamic acid for the treatment of postpartum haemorrhage



WHO 2017 PPH Guideline Recommendations

WHO strongly recommend early TXA treatment for PPH:

- within 3 hours of birth
- in addition to standard care including uterotonics, surgical and non-surgical interventions
- for all women with clinically diagnosed PPH
- following either vaginal birth or caesarean section
- regardless of the cause of haemorrhage

Give as soon as possible to maximize benefits
Use beyond 3 hours of birth does not confer any clinical benefit

Impact of treatment delay for severe bleeding

Tranexamic acid must be given urgently to save lives

Immediate treatment




70% improvement in survival

For every 15 minute delay




10% decrease in survival benefit After 3 hours



No benefit

Source: The Lancet (2017). Analysis of data for 40,000 trauma patients and women with severe bleeding after childbirth Credit: Rebeccah Robinson/LSHTM





Hours from giving birth to death

Dosage and administration

- Fixed dose of 1 g in 10 mL (100 mg/mL) intravenously at a rate of 1 mL/min
- Second dose if bleeding continues after 30 min or restarts within 24h of 1st dose
- Should not be mixed with blood for transfusion or solutions containing mannitol or penicillin



Conclusions

WHAT: TXA is a safe, affordable, live-saving treatment for PPH

Antifibrinolytic drug that inhibits blood clot breakdown (not a uterotonic)

WHO: Give 1 g TXA intravenously to all women with clinically diagnosed PPH after CS or vaginal birth, alongside other proven interventions, regardless of cause of bleeding

WHEN: Urgent treatment is critical (women bleed to death quickly and early TXA is effective)

Give within 3 hours of childbirth

Should be readily available at all times in emergency obstetric care facilities (heat stable - store at room temperature)

Thank you!

Questions?